ClinicalTrials.gg

Program

felzartamab

Also written as “Felzartamab”, “MOR202” and “TJ202 and Dexamethasone”.

Its studies are mostly in Glomerulonephritis, IGA · Multiple Myeloma · Glomerulonephritis, Membranous · Myasthenia Gravis · Graves Disease, led by 3 companies.

Furthest: phase 3, since Nov 11, 202415 company-led studies, 7 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen117 open or runningphase 3since Nov 11, 2024Oct 18, 2019Dec 1, 2026phase 3 · NCT06685757
TJ Biopharma30 open or runningphase 3since May 14, 2019Jan 15, 2019none ahead
Novartis10 open or runningphase 2since Jul 29, 2011Jul 29, 2011none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Jul 29, 2011.

  1. May 14, 2019Phase 3 study in Multiple MyelomaTJ Biopharma · NCT03952091 · 289 enrolled · China, Taiwan
  2. Oct 18, 2019Biogen's first study: phase 2 study in Glomerulonephritis, MembranousNew to BiogenBiogen · NCT04145440 · 31 enrolled · United States, Australia, Belgium and more
  3. Jan 18, 2021Phase 2 study in GlomerulonephritisBiogen · NCT04733040 · 24 enrolled · Georgia, Germany, Greece and more
  4. Sep 14, 2021Phase 2 study in Kidney DiseasesBiogen · NCT05065970 · 54 enrolled · United States, Australia, Belgium and more
  5. Nov 4, 2021Phase 1 study in Lupus Erythematosus, SystemicTJ Biopharma · NCT05140824 · 1 enrolled · China
  6. Sep 26, 2023Phase 1 study in Lupus NephritisBiogen · NCT06064929 · 14 enrolled · United States, Argentina, Australia and more
  7. Nov 11, 2024Phase 3 study in Antibody-mediated RejectionBiogen · NCT06685757 · 132 enrolled · United States, Argentina, Australia and more
  8. Apr 17, 2025Phase 3 study in Glomerulonephritis, IGABiogen · NCT06935357 · 454 planned · United States, Argentina, Australia and more
  9. Oct 17, 2025Phase 2 study in Microvascular InflammationBiogen · NCT07219043 · 81 planned · United States, Argentina, Australia and more
  10. Feb 26, 2026Phase 3 study in Antibody-mediated RejectionBiogen · NCT07444489 · 201 planned · United States, Canada
  11. Jul 20, 2026Phase 2 study in Graves DiseaseBiogen · NCT07722546 · 60 planned · United States, Puerto Rico
  12. Sep 30, 2026Primary completion moved from 2031-05-28 to 2031-12-31Date moved laterphase 3 · +7 months · NCT07444489
  13. Oct 16, 2026Phase 2 study in Glomerulonephritis, IGABiogen · NCT07889362 · 25 planned
  14. Nov 10, 2026Phase 2 study in Myasthenia GravisBiogen · NCT07939802 · 75 planned

Ahead

  1. Dec 1, 2026Primary completion: phase 3 study in Antibody-mediated RejectionBiogen · NCT06685757
  2. May 31, 2027Primary completion: phase 3 study in Glomerulonephritis, IGABiogen · NCT06935357
  3. Jan 31, 2028Primary completion: phase 2 study in Graves DiseaseBiogen · NCT07722546
  4. Feb 10, 2028Primary completion: phase 2 study in Microvascular InflammationBiogen · NCT07219043

TargetBeta

CD38 →read by rule
“A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 ”NCIt, by rule
“Lymphocyte differentiation antigen CD38 inhibitor”ChEMBL 37, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
daratumumabruleJohnson & Johnsonphase 444
isatuximabruleSanofiphase 323
mezagitamabruleTakedaphase 311
lumrotatugruleKeymed Biosciencesphase 310
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 35
sanritatugruleHangzhou Sumgen Biotechphase 35
CID-103ruleCASI Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 21
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 11

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07939802Myasthenia Gravis2Not yet recruitingBiogenSep 19, 202875
NCT07889362Glomerulonephritis, IGA2Not yet recruitingBiogenAug 13, 202825
NCT07722546Graves Disease · United States, Puerto Rico2RecruitingBiogenJan 31, 202860
NCT07444489Antibody-mediated Rejection · United States, Canada3By invitationBiogenDec 31, 2031201
NCT07219043Microvascular Inflammation · United States, Argentina, Australia and more2RecruitingBiogenFeb 10, 202881
NCT06935357Glomerulonephritis, IGA · United States, Argentina, Australia and more3RecruitingBiogenMay 31, 2027454
NCT06685757Antibody-mediated Rejection · United States, Argentina, Australia and more3Active, not recruitingBiogenDec 1, 2026132
NCT06064929Lupus Nephritis · United States, Argentina, Australia and more1CompletedBiogenJun 24, 202614
NCT05140824Lupus Erythematosus, Systemic · China1TerminatedTJ BiopharmaDec 14, 20221
NCT05065970Kidney Diseases · United States, Australia, Belgium and more2CompletedBiogenFeb 6, 202354
NCT04733040Glomerulonephritis · Georgia, Germany, Greece and more2CompletedBiogenDec 14, 202324
NCT04145440Glomerulonephritis, Membranous · United States, Australia, Belgium and more2CompletedBiogenJan 19, 202231
NCT03952091Multiple Myeloma · China, Taiwan3CompletedTJ BiopharmaJun 30, 2024289
NCT03860038Multiple Myeloma · China, Taiwan2CompletedTJ BiopharmaJan 28, 2023113
NCT01421186Multiple Myeloma · Austria, Germany2CompletedNovartisAug 202091

How it is read

Names in the registry

  • “Felzartamab”, 9 entries
  • “MOR202”, 2 entries
  • “TJ202 and Dexamethasone”, 1 entry
  • “TJ202, Lenalidomide and Dexamethasone”, 1 entry
  • “TJ202 injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.